Human medicines European public assessment report (EPAR): Rivastigmine 1 A Pharma, rivastigmine, Alzheimer Disease,Dementia,Parkinson Disease, Date of authorisation: 10/12/2009, Revision: 9, Status: Authorised
Keyword(s):
Keyword(s):
